Concepedia

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML

Claire Lucas, Laura J. Scott, Natasha Carmell, Alison Holcroft, Robert K. Hills, Alan K. Burnett, Richard E. Clark

Blood Advances · 2018 · 22 citations · 21 references

DOIFull text

Open access

Concepts

Abstract

Key Points PP2A inhibition occurs in AML by 2 different pathways: CIP2A in normal karyotype patients and SETBP1 in adverse karyotype patients. AKTS473 phosphorylation is a predictor of survival, and diagnostic levels of AKTS473 could be a novel biomarker in AML.

References

21

The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

David Grimwade, Helen M. Walker, Fiona Oliver et al. · Blood · 1998 · 2.6K citations · Full text

, , +12

Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

John Brognard, Amy S. Clark, Yucheng Ni et al. · PubMed · 2001 · 892 citations

, , +17

CIP2A Inhibits PP2A in Human Malignancies

Melissa R. Junttila, Pietri Puustinen, Minna Niemelä et al. · Cell · 2007 · 681 citations · Full text

, , +4

Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines

Kaname Nakatani, Devon A. Thompson, Andreas Barthel et al. · Journal of Biological Chemistry · 1999 · 474 citations · Full text

, , +15

Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

Alan K. Burnett, Nigel H. Russell, Robert K. Hills et al. · Journal of Clinical Oncology · 2013 · 415 citations · Full text

, , +16